Abstract
Background Immune-checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI-myocarditis can manifest concurrent generalized myositis, myasthenia-like syndrome, and respiratory muscle failure. Prognostic factors for this “cardiomyotoxicity” are lacking.
Methods A multicenter registry collected data retrospectively from 17 countries between 2014-2023. A multivariable cox regression model (hazard-ratio(HR), [95%confidence-interval]) was used to determine risk factors for the primary composite outcome: severe arrhythmia, heart failure, respiratory muscle failure, and/or cardiomyotoxicity-related death. Covariates included demographics, comorbidities, cardio-muscular symptoms, diagnostics, and treatments. Time-dependent covariates were used and missing data were imputed. A point-based prognostic risk score was derived and externally validated.
Results In 748 patients (67% male, age 23-94), 30-days incidence of the primary composite outcome, cardiomyotoxic death, and overall death were 33%, 13%, and 17% respectively. By multivariable analysis, the primary composite outcome was associated with active thymoma (HR=3.60[1.93-6.72]), presence of cardio-muscular symptoms (HR=2.60 [1.58-4.28]), low QRS-voltage on presenting electrocardiogram (HR for ≤0.5mV versus >1mV=2.08[1.31-3.30]), left ventricular ejection fraction (LVEF) <50% (HR=1.78[1.22-2.60]), and incremental troponin elevation (HR=1.86 [1.44-2.39], 2.99[1.91-4.65], 4.80[2.54-9.08], for 20, 200 and 2000-fold above upper reference limit, respectively). A prognostic risk score developed using these parameters showed good performance; 30-days primary outcome incidence increased gradually from 3.9%(risk-score=0) to 81.3%(risk-score≥4). This risk-score was externally validated in two independent French and US cohorts. This risk score was used prospectively in the external French cohort to identify low risk patients who were managed with no immunosuppression resulting in no cardio-myotoxic events.
Conclusions ICI-myocarditis can manifest with high morbidity and mortality. Myocarditis severity is associated with magnitude of troponin, thymoma, low-QRS voltage, depressed LVEF, and cardio-muscular symptoms. A risk-score incorporating these features performed well.
Trial registration number: NCT04294771 and NCT05454527
Structured Graphical Abstract Key Question: What predicts poor prognosis in ICI-associated myocarditis?
Key Finding: Troponin, thymoma, cardio-muscular symptoms, low QRS-voltage, and LVEF predicted negative outcomes. A risk score containing these features performed well.
Take-Home Message: ICI-myocarditis is part of a generalized myotoxicity and early risk-stratified early is possible.
Competing Interest Statement
International ICI-Myocarditis Registry: Osnat Itzakhi Ben Zadok (USA), Anita Deswal (USA), Franck Thuny (France), Anissa Bouali (France), Andrew Hughes (USA), Lisa Moser (USA), Maxime Faure (France), Rocio Baro Vila (Canada), Jesus Jimenez (USA), Seyed Ebrahim Kassaian (USA), Elise Paven (France), Elena Galli (France), Teresa Lopez Fernandez (Spain); Lucia Cobarro (Spain), Manhal Habib (Israel), Kazuko Tajiri (Japan), Fanny Rocher (France), Theodora Bejan-Angoulvant (France), Mehmet Asim Bilen (USA), Susmita Parashar (USA), Avirup Guha (USA), Wenjing Song (China), David Koenig (Switzerland), Kirsten Mertz (Switzerland), Carrie Lenneman (USA), Andrew Haydon (Australia), Chloe Lesiuk (France), Romain Tresorier (France), Yazeed Samara (USA), Christian Grohe (Germany), Pierre Yves Dietrich (Switzerland), Sean Tierney (USA), Elie Rassy (Lebanon), Elvire Mervoyer (France), Shigeaki Suzuki (Japan), Satoshi Fukushima (Japan), Avirup Guha (USA), Maxime Robert-Halabi (Canada), Ryota Morimoto (Japan), Kazuko Tajiri (Japan), Robert Copeland-Halperin (USA), Michael Layoun (USA), Jun Wang (China), Suran Fernando (Australia), Eugenia Rota (Italy), Yumi Katsume (Japan), Yukiko Kiniwa (Japan), Ellen Warner (Canada), Nobuhiko Seki (Japan), Theresa Ruf (Germany), Jess DeLaune (USA), Nazanin Aghel (Canada)
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Vanderbilt University medical center gave ethical approval for this work IRB:181337
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The international ICI myocarditis registry is open to the entire scientific community based on a 'reciprocity principle', i.e., access to the cohort will only be allowed to those entities also willing to share data. Access to the database is granted to researchers and clinicians who are part of the consortium and have been approved by the project's coordination (Pr Joe-Elie SALEM and Dr Javid MOSLEHI).
